KROS — Keros Therapeutics, Inc. stock price, charts and financials

QT34Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (NASDAQ: KROS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
10.25
+0.14+1.38%
OverviewShort InterestFilings
KROSQT34Keros Therapeutics, Inc.·NASDAQ
10.25+1.38%
Filing
Up 1.4% — Filed an 8-K material-event report (2026-08-03) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E6.66EPS (ttm)1.54Insider Own46.51%Shs Outstand32.00MPerf Week1.79%
Market Cap327.98MForward P/E-EPS next Y-5.49Insider Trans-0.15%Shs Float29.53MPerf Month-7.07%
Enterprise Value60.98MPEG-EPS next Q-Inst Own-Short Float3.59%Perf Quarter-12.47%
Income64.00MP/S1.33EPS this Y-457.45%Inst Trans-Short Ratio3.44Perf Half Y-44.29%
Sales246.00MP/B1.15EPS next Y0.29%ROA-27.26%Short Interest1.06MPerf YTD-49.66%
Book/sh8.94P/C1.17EPS next 5Y-ROE-17.04%52W High22.55 -54.55%Perf Year-28.42%
Cash/sh8.78P/FCF-EPS past 3/5Y-ROIC-34.46%52W Low9.69 5.78%Perf 3Y-75.58%
Dividend Est.-EV/EBITDA0.69Sales past 3/5Y-Gross Margin96.48%Volatility4.52% 4.88%Perf 5Y-71.99%
Dividend TTM-EV/Sales0.25EPS Y/Y TTM130.80%Oper. Margin-332.55%ATR (14)0.50Perf 10Y-
Dividend Ex-Date-Quick Ratio22.62Sales Y/Y TTM6050.00%Profit Margin-256.60%RSI (14)45.15Recom2.41
Dividend Gr. 3/5Y-Current Ratio22.62EPS Q/Q-133.43%SMA20-3.27%Beta1.00Target Price20.33
Payout0.00%Debt/Eq0.05Sales Q/Q-100.00%SMA50-3.96%Rel Volume0.97Prev Close10.11
Employees78LT Debt/Eq0.05EarningsNov 04SMA200-27.84%Avg Volume285.01KPrice10.25
IPO DateApr 08, 2020Option/ShortYes / YesEPS/Sales Surpr.-18.30% -80.97%Net Debt/EBITDA2.99Volume276,933Change1.38%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedH.C. WainwrightBuy$20
Aug-04-26ReiteratedWells FargoOverweight$18
Aug-04-26ReiteratedLeerink PartnersOutperform$23
Jun-10-25DowngradeB of A SecuritiesBuy → Neutral
Jan-21-25DowngradeCantor FitzgeraldOverweight → Neutral
Jan-17-25DowngradeWedbushOutperform → Neutral
Dec-16-24DowngradeGuggenheimBuy → Neutral
Dec-12-24DowngradeWilliam BlairOutperform → Market Perform
Dec-12-24DowngradeBTIGBuy → Neutral
Dec-12-24DowngradeTD CowenBuy → Hold
Latest News
Company

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2462444002001010
Cost of Goods Sold Incl. D&A02000011710
Gross Profit24624340020-1-70
Selling, General and Administrative Excl. Other4547413528211232
Research and Development1591301741358755341710
Other Operating Expense-2-5-100000-1
Operating Income4471-211-170-115-56-47-11-2
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)282124171001-21
Net Income Before Taxes7092-187-153-105-57-46-12-1
Income Taxes750002000
Consolidated Net Income6487-187-153-105-59-45-12-1
Net Income From Continuing Operations6487-187-153-105-59-45-12-1
Net Income6487-187-153-105-59-45-12-1
EPS (Recurring)1.582.34-5.00-5.20-4.15-2.52-2.93-1.39-0.15
EPS (Basic, Before Extraordinaries)1.582.34-5.00-5.20-4.15-2.52-2.93-1.39-0.15
EPS (Diluted)1.542.30-5.00-5.20-4.15-2.52-2.93-1.39-0.15
EBITDA8993-186-152-104-56-45-12-1
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio6.668.85———————
Price To Sales Ratio1.713.09146.43——67.29———
Gross Margin100.0099.59100.00——100.00—-70.000.00
Operating Margin17.8929.10-5,275.00——-280.00—-110.00-20.00
Net Margin26.0235.66-4,675.00——-295.00—-120.00-10.00
Shares Outstanding4137372925231699
Market Capitalization4207535861,1531,2011,3461,129——
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$23.63$19.75$15.88$12.00$8.12● Close Price0.00M3.99M7.98M11.96M15.95MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BIENAIME JEAN JACQUESDirectorJul 15 '26Buy10.611,00010,61018,592Jul 17
BIENAIME JEAN JACQUESDirectorJun 15 '26Buy10.191,00010,19017,592Jun 17
Newton Charles W.DirectorJun 11 '26Sale10.045505,52212,665Jun 15
Farzan NimaDirectorJun 04 '26Sale10.732,62528,1669,767Jun 08
Knowles JuliusDirectorJun 04 '26Sale10.732,62528,16610,958Jun 08
Seth AlpnaDirectorJun 04 '26Sale10.722,62528,1409,767Jun 05
BIENAIME JEAN JACQUESDirectorMay 15 '26Buy10.581,00010,5809,450May 19
BIENAIME JEAN JACQUESDirectorApr 15 '26Buy11.701,00011,7008,450Apr 17
Seehra JasbirCHIEF EXECUTIVE OFFICERApr 02 '26Option Exercise0.3055,00016,500440,708Apr 06
BIENAIME JEAN JACQUESDirectorMar 09 '26Buy11.212,00022,4207,450Mar 11
Seehra JasbirCHIEF EXECUTIVE OFFICERFeb 19 '26Sale16.177,015113,433385,708Feb 20
Lerner Lorena RaquelChief Science OfficerFeb 18 '26Sale16.353,87363,32431,127Feb 20
Cho EstherSVP, General CounselFeb 18 '26Sale16.354,74577,58139,755Feb 20
Regnante KeithCHIEF FINANCIAL OFFICERFeb 18 '26Sale16.354,73977,48339,261Feb 20
Pontifax Management 4 G.P. (2015) Ltd.10% OwnerOct 15 '25Sale17.75155,2622,755,9010Oct 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.